Stockhead | Air supply: The ASX medtechs tackling respiratory illnesses
15 July 2024
Lumos Diagnostics has been included in a Stockhead article spotlighting medtech companies addressing respiratory illness.
Journalist Nadine McGrath spoke with Lumos Non-Executive Chair, Sam Lanyon, about how Lumos’ point-of-care diagnostic tool, FebriDx, is helping clinicians to better manage patients with respiratory infections in healthcare settings.
Here’s an excerpt:
“If it’s bacterial then obviously the illness will need antibiotics and if it’s viral then it may be more infectious and transmissible,” Lanyon says.
With antimicrobial resistance (AMR) considered by the World Health Organisation one of the top global public health and development threats, avoiding unnecessary use of antibiotics has become paramount, which is where LDX’s FebriDx is finding value.
“The reason why we developed the product we did is the first question a clinician is going to have to answer is whether the illness is caused by a bacteria or virus because the treatment options are clearer once that has been established,” Lanyon says.”
Click to read the full article
Journalist Nadine McGrath spoke with Lumos Non-Executive Chair, Sam Lanyon, about how Lumos’ point-of-care diagnostic tool, FebriDx, is helping clinicians to better manage patients with respiratory infections in healthcare settings.
Here’s an excerpt:
“If it’s bacterial then obviously the illness will need antibiotics and if it’s viral then it may be more infectious and transmissible,” Lanyon says.
With antimicrobial resistance (AMR) considered by the World Health Organisation one of the top global public health and development threats, avoiding unnecessary use of antibiotics has become paramount, which is where LDX’s FebriDx is finding value.
“The reason why we developed the product we did is the first question a clinician is going to have to answer is whether the illness is caused by a bacteria or virus because the treatment options are clearer once that has been established,” Lanyon says.”
Click to read the full article
